Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells

Altering the Tropism of Lentiviral Vectors through Pseudotyping

“…In concert with a codon-optimized HIV-1 gagpol coding region, these producer cells could make lentiviral pseudotyped particles with titers up to 10 7 TU/ml (20 TU/cell/day) for at least three months in culture. Compared to vectors pseudotyped with VSV-G, the gammaretrovirus pseudotypes were relatively stable at 37°C and were resistant to inactivation by freeze/thaw cycling or incubation with human sera [Strang, 2004]. More recently, Strang et al [Strang, 2005] established stable producer cell lines for HIV-1 vectors pseudotyped with the alphavirus RRV and SFV E2E1 GPs.…”

Analysis of human immunodeficiency virus type 1 vector cis- and trans-acting elements production by means of Semliki Forest virus

“…7 Recombinant lentiviral particle production is obtained by transiently expressing the viral structural components along with the transfer vector 1 or, to a lesser degree, by the use of stable vector-producing cell lines. [8][9][10][11] For clinical application, vectors produced by stable cell lines could be preferred over the transiently generated ones, as in-depth molecular characterization of the producer line ensures a continuous source of vector particles and their extensive quality control, reducing therefore batchto-batch variation and allowing higher level of safety. Indeed, several stable packaging cell lines have been generated.…”

“…Indeed, several stable packaging cell lines have been generated. [9][10][11] However, this approach is laborious and time-consuming, and the toxicity of lentiviral (enzymes and accessory) proteins as well as the fusogenicity of the rhabdovirus vesicular stomatitis virus G protein (VSV-G), most commonly used to pseudotype HIV-1 vector particles, requires tight control of gene(s) expression, 11 complicating constitutive production of recombinant virions. The first clinical trial by means of an HIV-1-based vector has indeed been pursued by scaling up transiently produced lentiviral particles.…”

Lentiviral Vectors in Immunotherapy

“…An ideal immunotherapeutic approach would be to use lentiviral vectors to deliver the antigen of interest together with the three signals required for the desired T cell polarisation. Lentivectors have been extensively used for this purpose, because they are particularly effective in transducing DCs without affecting their functionality, unlike other vectors such as those based on adenoviruses [8,[19][20][21][22][23][24][25][26]. In fact, the stable integration of the lentivector genome allows longterm, sustained transgene expression [1,9].…”